Behavioral effects of neuropeptides in rodent models of depression and anxiety

Adams, 1995, A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder, J Clin Psychopharmacol, 15, 428, 10.1097/00004714-199512000-00007 Al Chawaf, 2007, Regulation of neurite growth in immortalized mouse hypothalamic neurons and rat hippocampal primary cultures by teneurin C-terminal-associated peptide-1, Neuroscience, 144, 1241, 10.1016/j.neuroscience.2006.09.062 Al Chawaf, 2007, Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1), Peptides, 28, 1406, 10.1016/j.peptides.2007.05.014 Anisman, 1980, Escape deficits induced by uncontrollable stress: antagonism by dopamine and norepinephrine agonists, Behav Neural Biol, 28, 34, 10.1016/S0163-1047(80)93132-5 Appenrodt, 1998, Vasopressin administration modulates anxiety-related behavior in rats, Physiol Behav, 64, 543, 10.1016/S0031-9384(98)00119-X Arborelius, 1999, The role of corticotropin-releasing factor in depression and anxiety disorders, J Endocrinol, 160, 1, 10.1677/joe.0.1600001 Arletti, 1987, Influence of protease inhibitors on the antidepressant activity of oxytocin, Neuropeptides, 10, 241, 10.1016/0143-4179(87)90074-6 Arletti, 1987, Oxytocin acts as an antidepressant in two animal models of depression, Life Sci, 41, 1725, 10.1016/0024-3205(87)90600-X Armario, 2008, Long-term neuroendocrine and behavioural effects of a single exposure to stress in adult animals, Neurosci Biobehav Rev, 32, 1121, 10.1016/j.neubiorev.2008.04.003 Asakawa, 1998, Endomorphins have orexigenic and anxiolytic activities in mice, Neuroreport, 9, 2265, 10.1097/00001756-199807130-00022 Bacchi, 2006, Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze, Peptides, 27, 3202, 10.1016/j.peptides.2006.07.020 Bakharev, 1986, Psychotropic properties of oxytocin, Neurosci Behav Physiol, 16, 160, 10.1007/BF01186517 Ballard, 2001, Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist, Eur J Pharmacol, 412, 255, 10.1016/S0014-2999(01)00724-5 Barr, 2006, A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests, Neurosci Lett, 405, 111, 10.1016/j.neulet.2006.06.033 Becker, 2008, Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin, Mol Psychiatry, 13, 1079, 10.1038/sj.mp.4002097 Beiderbeck, 2007, Differences in intermale aggression are accompanied by opposite vasopressin release patterns within the septum in rats bred for low and high anxiety, Eur J Neurosci, 26, 3597, 10.1111/j.1460-9568.2007.05974.x Beinfeld, 1981, The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay, Brain Res, 212, 51, 10.1016/0006-8993(81)90031-7 Beinfeld, 1982, Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei, Brain Res, 238, 260, 10.1016/0006-8993(82)90794-6 Bing, 1993, Anxiolytic-like action of centrally administered galanin, Neurosci Lett, 164, 17, 10.1016/0304-3940(93)90846-D Binneman, 2008, A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression, Am J Psychiatry, 165, 617, 10.1176/appi.ajp.2008.07071199 Blanchard, 2003, The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic, Eur J Pharmacol, 463, 97, 10.1016/S0014-2999(03)01276-7 Bleickardt, 2009, Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior, Psychopharmacology (Berl), 202, 711, 10.1007/s00213-008-1354-x Bocheva, 2008, Effect of Tyr-MIF-1 peptides on blood ACTH and corticosterone concentration induced by three experimental models of stress, Auton Autacoid Pharmacol, 28, 117, 10.1111/j.1474-8673.2008.00425.x Borsini, 1988, Is the forced swimming test a suitable model for revealing antidepressant activity?, Psychopharmacology (Berl), 94, 147, 10.1007/BF00176837 Britton, 2000, Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze, Peptides, 21, 37, 10.1016/S0196-9781(99)00169-2 Brocco, 2008, Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents, Eur Neuropsychopharmacol, 18, 729, 10.1016/j.euroneuro.2008.06.002 Broqua, 1995, Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures, Behav Pharmacol, 6, 215, 10.1097/00008877-199504000-00001 Bujdoso, 2001, Behavioral and neuroendocrine actions of endomorphin-2, Peptides, 22, 1459, 10.1016/S0196-9781(01)00466-1 Bujdoso, 2001, Effects of endomorphin-1 on open-field behavior and on the hypothalamic-pituitary-adrenal system, Endocrine, 14, 221, 10.1385/ENDO:14:2:221 Burbach, 1983, Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis, J Biol Chem, 258, 1487, 10.1016/S0021-9258(18)33011-4 Caldwell, 2008, Vasopressin: behavioral roles of an “original” neuropeptide, Prog Neurobiol, 84, 1, 10.1016/j.pneurobio.2007.10.007 Carvalho, 2008, Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin, Peptides, 29, 1191, 10.1016/j.peptides.2008.02.014 Cassella, 1985, Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats, Psychopharmacology (Berl), 87, 278, 10.1007/BF00432707 Celis, 1971, Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone, Proc Natl Acad Sci USA, 68, 1428, 10.1073/pnas.68.7.1428 Chaki, 2006, Non-monoamine-based approach for the treatment of depression and anxiety disorders, Recent Pat CNS Drug Discov, 1, 1, 10.2174/157488906775245318 Chenu, 2006, Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test, Behav Brain Res, 172, 256, 10.1016/j.bbr.2006.05.011 Crawley, 1995, Biological actions of galanin, Regul Pept, 59, 1, 10.1016/0167-0115(95)00083-N Cryan, 2002, Assessing antidepressant activity in rodents: recent developments and future needs, Trends Pharmacol Sci, 23, 238, 10.1016/S0165-6147(02)02017-5 Cryan, 2005, The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice, Neurosci Biobehav Rev, 29, 571, 10.1016/j.neubiorev.2005.03.009 Cryan, 2005, Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test, Neurosci Biobehav Rev, 29, 547, 10.1016/j.neubiorev.2005.03.008 Dableh, 2005, Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat, Eur J Pharmacol, 507, 99, 10.1016/j.ejphar.2004.11.024 Davis, 1979, Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm, Psychopharmacology (Berl), 62, 1, 10.1007/BF00426027 Davis, 1993, Fear-potentiated startle: a neural and pharmacological analysis, Behav Brain Res, 58, 175, 10.1016/0166-4328(93)90102-V de Groote, 2005, Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists, J Neurochem, 94, 45, 10.1111/j.1471-4159.2005.03164.x Deak, 1999, The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress, Endocrinology, 140, 79, 10.1210/en.140.1.79 Duarte, 2004, Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats, Behav Brain Res, 154, 501, 10.1016/j.bbr.2004.03.020 Dunn, 1990, Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?, Brain Res Brain Res Rev, 15, 71, 10.1016/0165-0173(90)90012-D Ebner, 2004, Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats, Proc Natl Acad Sci USA, 101, 4280, 10.1073/pnas.0400794101 Ebner, 2006, The role of substance P in stress and anxiety responses, Amino Acids, 31, 251, 10.1007/s00726-006-0335-9 Echevarria, 2005, Administration of the galanin antagonist M40 into lateral septum attenuates shock probe defensive burying behavior in rats, Neuropeptides, 39, 445, 10.1016/j.npep.2005.06.004 Ehrensing, 1978, Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression, Am J Psychiatry, 135, 562, 10.1176/ajp.135.5.562 Ehrensing, 1974, Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study, Arch Gen Psychiatry, 30, 63, 10.1001/archpsyc.1974.01760070047007 Ehrensing, 1994, Improvement in major depression after low subcutaneous doses of MIF-1, J Affect Disord, 31, 227, 10.1016/0165-0327(94)90098-1 Everts, 1999, Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats, Behav Brain Res, 99, 7, 10.1016/S0166-4328(98)00004-7 Feighner, 2000, A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression, J Affect Disord, 61, 119, 10.1016/S0165-0327(99)00187-1 Feighner, 2001, Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression, Int Clin Psychopharmacol, 16, 345, 10.1097/00004850-200111000-00005 Feighner, 2003, Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment, Int J Neuropsychopharmacol, 6, 207, 10.1017/S1461145703003481 Fendt, 2009, Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect, Psychopharmacology (Berl), 206, 291, 10.1007/s00213-009-1610-8 Fichna, 2007, Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice, Neuropsychopharmacology, 32, 813, 10.1038/sj.npp.1301149 File, 2000, NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats, Psychopharmacology (Berl), 152, 105, 10.1007/s002130000513 File, 1980, The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs, J Neurosci Methods, 2, 219, 10.1016/0165-0270(80)90012-6 File, 1978, Can social interaction be used to measure anxiety?, Br J Pharmacol, 62, 19, 10.1111/j.1476-5381.1978.tb07001.x Fisher, 2006, Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor, J Med Chem, 49, 307, 10.1021/jm050644n Floren, 2005, Multiple interaction sites of galnon trigger its biological effects, Neuropeptides, 39, 547, 10.1016/j.npep.2005.09.005 Frank, 2008, The vasopressin system—from antidiuresis to psychopathology, Eur J Pharmacol, 583, 226, 10.1016/j.ejphar.2007.11.063 Frankland, 1997, Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat, J Neurosci, 17, 1838, 10.1523/JNEUROSCI.17-05-01838.1997 Fukunaga, 1999, Effects of Tyr-MIF-1 on stress-induced analgesia and the blockade of development of morphine tolerance by stress in mice, Jpn J Pharmacol, 79, 231, 10.1254/jjp.79.231 Gehlert, 2005, Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor, Eur J Pharmacol, 509, 145, 10.1016/j.ejphar.2004.12.030 Geoffroy, 1990, Effect of imipramine in the “learned helplessness” model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine, Psychopharmacology (Berl), 101, 371, 10.1007/BF02244056 Goldberg, 1998, Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain, J Pharmacol Exp Ther, 286, 1007 Goyal, 2006, Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats, Pharmacol Biochem Behav, 85, 369, 10.1016/j.pbb.2006.09.004 Griebel, 1999, Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?, Pharmacol Ther, 82, 1, 10.1016/S0163-7258(98)00041-2 Griebel, 2002, Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders, Proc Natl Acad Sci USA, 99, 6370, 10.1073/pnas.092012099 Griebel, 2003, The vasopressin V1b receptor as a therapeutic target in stress-related disorders, Curr Drug Targets CNS Neurol Disord, 2, 191, 10.2174/1568007033482850 Guastella, 2009, A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder, Psychoneuroendocrinology, 34, 917, 10.1016/j.psyneuen.2009.01.005 Harris, 1998, Benzodiazepine-induced amnesia in rats: reinstatement of conditioned performance by noxious stimulation on test, Behav Neurosci, 112, 183, 10.1037/0735-7044.112.1.183 Heilig, 1992, Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test, Regul Pept, 41, 61, 10.1016/0167-0115(92)90514-U Heilig, 1989, Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models, Psychopharmacology (Berl), 98, 524, 10.1007/BF00441953 Heinrichs, 2003, Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress, Biol Psychiatry, 54, 1389, 10.1016/S0006-3223(03)00465-7 Heinrichs, 2002, Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist, Neuropsychopharmacology, 27, 194, 10.1016/S0893-133X(02)00299-3 Heinrichs, 1995, The role of CRF in behavioral aspects of stress, Ann N Y Acad Sci, 771, 92, 10.1111/j.1749-6632.1995.tb44673.x Heinrichs, 1994, Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity, Neuropsychopharmacology, 11, 179, 10.1038/sj.npp.1380104 Henry, 2006, The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress, J Neurosci, 26, 9142, 10.1523/JNEUROSCI.1494-06.2006 Hernando, 1994, The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice, Eur J Pharmacol, 261, 257, 10.1016/0014-2999(94)90115-5 Hodgson, 2007, Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression, Pharmacol Biochem Behav, 86, 431, 10.1016/j.pbb.2006.12.021 Hokfelt, 2003, Neuropeptides: opportunities for drug discovery, Lancet Neurol, 2, 463, 10.1016/S1474-4422(03)00482-4 Hokfelt, 2000, Neuropeptides—an overview, Neuropharmacology, 39, 1337, 10.1016/S0028-3908(00)00010-1 Holmes, 2003, Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders, Trends Pharmacol Sci, 24, 580, 10.1016/j.tips.2003.09.011 Holsboer, 2008, Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists, Eur J Pharmacol, 583, 350, 10.1016/j.ejphar.2007.12.032 Hughes, 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc Natl Acad Sci USA, 87, 6728, 10.1073/pnas.87.17.6728 Ishida, 2007, Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor, Hippocampus, 17, 271, 10.1002/hipo.20264 Jones, 1998, The behavioural effects of corticotropin-releasing factor-related peptides in rats, Psychopharmacology (Berl), 138, 124, 10.1007/s002130050654 Josselyn, 1995, The CCKB antagonist, L-365,260, attenuates fear-potentiated startle, Peptides, 16, 1313, 10.1016/0196-9781(95)02013-M Kametani, 1983, The reversal effect of antidepressants on the escape deficit induced by inescapable shock in rats, Psychopharmacology (Berl), 80, 206, 10.1007/BF00436153 Karlsson, 2005, Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice, Pharmacol Biochem Behav, 80, 427, 10.1016/j.pbb.2004.12.009 Kask, 1998, Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats, Regul Pept, 75-76, 255, 10.1016/S0167-0115(98)00076-7 Kask, 1997, Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease, Life Sci, 60, 1523, 10.1016/S0024-3205(96)00624-8 Kastin, 1978, Enkephalin and other peptides reduce passiveness, Pharmacol Biochem Behav, 9, 515, 10.1016/0091-3057(78)90051-5 Katz, 1982, Animal model of depression: pharmacological sensitivity of a hedonic deficit, Pharmacol Biochem Behav, 16, 965, 10.1016/0091-3057(82)90053-3 Keck, 2001, The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats, Eur J Neurosci, 13, 373, 10.1046/j.0953-816X.2000.01383.x Kehne, 1988, Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm, Psychopharmacology (Berl), 94, 8, 10.1007/BF00735872 Keller, 2006, Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder, Biol Psychiatry, 59, 216, 10.1016/j.biopsych.2005.07.013 Khoshbouei, 2002, Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala, Pharmacol Biochem Behav, 71, 407, 10.1016/S0091-3057(01)00683-9 Khoshbouei, 2002, Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress, Neuropsychopharmacology, 27, 25, 10.1016/S0893-133X(01)00424-9 Kirsch, 2005, Oxytocin modulates neural circuitry for social cognition and fear in humans, J Neurosci, 25, 11489, 10.1523/JNEUROSCI.3984-05.2005 Klenerova, 2009, Modulary effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field, J Physiol Pharmacol, 60, 57 Kokare, 2005, Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats, Brain Res, 1043, 107, 10.1016/j.brainres.2005.02.038 Kostowski, 1991, MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression, Peptides, 12, 915, 10.1016/0196-9781(91)90037-P Kozicz, 2007, On the role of urocortin 1 in the non-preganglionic Edinger-Westphal nucleus in stress adaptation, Gen Comp Endocrinol, 153, 235, 10.1016/j.ygcen.2007.04.005 Kramer, 1998, Distinct mechanism for antidepressant activity by blockade of central substance P receptors, Science, 281, 1640, 10.1126/science.281.5383.1640 Kramer, 1995, A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder, Biol Psychiatry, 37, 462, 10.1016/0006-3223(94)00190-E Kramer, 2004, Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression, Neuropsychopharmacology, 29, 385, 10.1038/sj.npp.1300260 Krase, 1994, Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats, Behav Brain Res, 63, 81, 10.1016/0166-4328(94)90053-1 Kunzel, 2003, Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects, J Psychiatr Res, 37, 525, 10.1016/S0022-3956(03)00070-0 Kuteeva, 2008, Galanin, galanin receptor subtypes and depression-like behaviour, Cell Mol Life Sci, 65, 1854, 10.1007/s00018-008-8160-9 Kuteeva, 2007, Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat, Eur Neuropsychopharmacol, 17, 64, 10.1016/j.euroneuro.2006.03.003 Kuteeva, 2008, Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level, Neuropsychopharmacology, 33, 2573, 10.1038/sj.npp.1301660 Lang, 2000, Fear and anxiety: animal models and human cognitive psychophysiology, J Affect Disord, 61, 137, 10.1016/S0165-0327(00)00343-8 Lee, 2007, Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin, Brain Res, 1156, 152, 10.1016/j.brainres.2007.04.042 Lee, 2005, Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin, Neuropsychopharmacology, 30, 1883, 10.1038/sj.npp.1300722 Levy, 1982, Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial, Biol Psychiatry, 17, 259 Lewis, 2001, Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor, Proc Natl Acad Sci USA, 98, 7570, 10.1073/pnas.121165198 Liebsch, 1996, Septal vasopressin modulates anxiety-related behaviour in rats, Neurosci Lett, 217, 101, 10.1016/0304-3940(96)13069-X Lister, 1990, Ethologically-based animal models of anxiety disorders, Pharmacol Ther, 46, 321, 10.1016/0163-7258(90)90021-S Lovejoy, 2006, Teneurin C-terminal associated peptides: an enigmatic family of neuropeptides with structural similarity to the corticotropin-releasing factor and calcitonin families of peptides, Gen Comp Endocrinol, 148, 299, 10.1016/j.ygcen.2006.01.012 Lu, 2005, A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus, Proc Natl Acad Sci USA, 102, 874, 10.1073/pnas.0408891102 Lundstrom, 2005, Galanin and its receptors in neurological disorders, Neuromolecular Med, 7, 157, 10.1385/NMM:7:1-2:157 Lyudyno, 2008, The role of the neuropeptide galanin in forming type-specific behavioral characteristics, Neurosci Behav Physiol, 38, 93, 10.1007/s11055-008-0013-3 Malkani, 2000, Induction of NGFI-B mRNA following contextual fear conditioning and its blockade by diazepam, Brain Res Mol Brain Res, 80, 153, 10.1016/S0169-328X(00)00130-3 Malkesman, 2007, Assessment of antidepressant and anxiolytic properties of NK1 antagonists and substance P in Wistar Kyoto rats, Physiol Behav, 90, 619, 10.1016/j.physbeh.2006.11.014 Mansbach, 1997, Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist, Eur J Pharmacol, 323, 21, 10.1016/S0014-2999(97)00025-3 Mathe, 2007, Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?, Physiol Behav, 92, 226, 10.1016/j.physbeh.2007.05.016 Mathew, 2008, Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics, Am J Med Genet C Semin Med Genet, 148C, 89, 10.1002/ajmg.c.30172 Matto, 1997, The effect of drugs acting on CCK receptors and rat free exploration in the exploration box, J Physiol Pharmacol, 48, 239 McCarthy, 1996, An anxiolytic action of oxytocin is enhanced by estrogen in the mouse, Physiol Behav, 60, 1209, 10.1016/S0031-9384(96)00212-0 Millan, 2003, The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines, Eur J Pharmacol, 463, 67, 10.1016/S0014-2999(03)01275-5 Millan, 2001, Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent, Neuropsychopharmacology, 25, 585, 10.1016/S0893-133X(01)00244-5 Mitchell, 1998, The role of corticotropin releasing factor in depressive illness: a critical review, Neurosci Biobehav Rev, 22, 635, 10.1016/S0149-7634(97)00059-6 Mitsukawa, 2008, Galanin, galanin receptors and drug targets, Cell Mol Life Sci, 65, 1796, 10.1007/s00018-008-8153-8 Moller, 1999, Anxiogenic-like action of galanin after intra-amygdala administration in the rat, Neuropsychopharmacology, 21, 507, 10.1016/S0893-133X(98)00102-X Montgomery, 2006, Efficacy and safety of 30mg/d and 45mg/d nemifitide compared to placebo in major depressive disorder, Int J Neuropsychopharmacol, 9, 517, 10.1017/S1461145705006139 Moreau, 1997, Urocortin, a novel neuropeptide with anxiogenic-like properties, Neuroreport, 8, 1697, 10.1097/00001756-199705060-00027 Nair, 1971, Isolation and structure of hypothalamic MSH release-inhibition hormone, Biochem Biophys Res Commun, 43, 1376, 10.1016/S0006-291X(71)80026-8 Nakajima, 1998, Neuropeptide Y produces anxiety via Y2-type receptors, Peptides, 19, 359, 10.1016/S0196-9781(97)00298-2 Neumann, 2008, Brain oxytocin: a key regulator of emotional and social behaviours in both females and males, J Neuroendocrinol, 20, 858, 10.1111/j.1365-2826.2008.01726.x Neumann, 2000, Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats, Neuroscience, 95, 567, 10.1016/S0306-4522(99)00433-9 Neumann, 2000, Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus, J Neuroendocrinol, 12, 235, 10.1046/j.1365-2826.2000.00442.x Nicolau, 2005, Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers, Biopharm Drug Dispos, 26, 379, 10.1002/bdd.470 Nielsen, 2006, Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?, Life Sci, 78, 909, 10.1016/j.lfs.2005.06.003 Nielsen, 2004, Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice, Eur J Pharmacol, 499, 135, 10.1016/j.ejphar.2004.07.091 Ogren, 2006, Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders, CNS Drugs, 20, 633, 10.2165/00023210-200620080-00003 Okuyama, 1999, Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001, J Pharmacol Exp Ther, 289, 926 Olson, 1980, MIF-I suppresses deprivation-induced fluid consumption in rats, Peptides, 1, 353, 10.1016/0196-9781(80)90014-5 Overstreet, 2002, Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists, Behav Genet, 32, 335, 10.1023/A:1020262205227 Overstreet, 1993, The Flinders sensitive line rats: a genetic animal model of depression, Neurosci Biobehav Rev, 17, 51, 10.1016/S0149-7634(05)80230-1 Overstreet, 2004, Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression, Eur J Pharmacol, 497, 49, 10.1016/j.ejphar.2004.06.035 Overstreet, 2005, Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat, Pharmacol Biochem Behav, 82, 223, 10.1016/j.pbb.2005.07.021 Overstreet, 2004, Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression, Psychopharmacology (Berl), 175, 303, 10.1007/s00213-004-1815-9 Overstreet, 2004, Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression, Eur J Pharmacol, 492, 195, 10.1016/j.ejphar.2004.04.010 Overstreet, 2005, Can CRF1 receptor antagonists become antidepressant and/or Anxiolytic Agents?, Drug development research, 65, 191, 10.1002/ddr.20023 Pan, 2007, From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptides, Peptides, 28, 2411, 10.1016/j.peptides.2007.10.006 Pan, 2008, Urocortin and the brain, Prog Neurobiol, 84, 148, 10.1016/j.pneurobio.2007.10.008 Pande, 1999, Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder, Biol Psychiatry, 46, 860, 10.1016/S0006-3223(99)00090-6 Papp, 2000, The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats, Behav Brain Res, 115, 19, 10.1016/S0166-4328(00)00230-8 Pellow, 1987, Can anti-panic drugs antagonise the anxiety produced in the rat by drugs acting at the GABA-benzodiazepine receptor complex?, Neuropsychobiology, 17, 60, 10.1159/000118341 Petersen, 1981, A water lick conflict paradigm using drug experienced rats, Psychopharmacology (Berl), 75, 236, 10.1007/BF00432430 Pignatiello, 1989, MIF-1 is active in a chronic stress animal model of depression, Pharmacol Biochem Behav, 32, 737, 10.1016/0091-3057(89)90027-0 Porsolt, 1978, Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur J Pharmacol, 47, 379, 10.1016/0014-2999(78)90118-8 Porsolt, 1977, Depression: a new animal model sensitive to antidepressant treatments, Nature, 266, 730, 10.1038/266730a0 Pucilowski, 1982, MIF-1 facilitates passive avoidance retention, Pol J Pharmacol Pharm, 34, 107 Pulvirenti, 1988, Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats, Eur J Pharmacol, 151, 289, 10.1016/0014-2999(88)90810-2 Qian, 2004, Cloning and characterization of teneurin C-terminus associated peptide (TCAP)-3 from the hypothalamus of an adult rainbow trout (Oncorhynchus mykiss), Gen Comp Endocrinol, 137, 205, 10.1016/j.ygcen.2004.02.007 Radulovic, 1999, Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2, J Neurosci, 19, 5016, 10.1523/JNEUROSCI.19-12-05016.1999 Rajarao, 2007, Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon, Neuropeptides, 41, 307, 10.1016/j.npep.2007.05.001 Rataud, 1991, Anxiolytic effect of CCK-antagonists on plus-maze behavior in mice, Brain Res, 548, 315, 10.1016/0006-8993(91)91139-R Redrobe, 2002, The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test, Neuropsychopharmacology, 26, 615, 10.1016/S0893-133X(01)00403-1 Redrobe, 2002, Neuropeptide Y (NPY) and depression: from animal studies to the human condition, Life Sci, 71, 2921, 10.1016/S0024-3205(02)02159-8 Reyes, 2001, Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors, Proc Natl Acad Sci USA, 98, 2843, 10.1073/pnas.051626398 Rezayat, 2005, Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety, Physiol Behav, 84, 775, 10.1016/j.physbeh.2005.03.002 Ring, 2006, Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications, Psychopharmacology (Berl), 185, 218, 10.1007/s00213-005-0293-z Ring, 2009, Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist, Neuropharmacology Ripoll, 2006, The four-plates test: anxiolytic or analgesic paradigm?, Prog Neuropsychopharmacol Biol Psychiatry, 30, 873, 10.1016/j.pnpbp.2005.11.036 Risbrough, 2003, Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice, Psychopharmacology (Berl), 170, 178, 10.1007/s00213-003-1535-6 Rodgers, 1997, Anxiety, defence and the elevated plus-maze, Neurosci Biobehav Rev, 21, 801, 10.1016/S0149-7634(96)00058-9 Rotzinger, 2003, Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models, J Psychiatry Neurosci, 28, 171 Rupniak, 2003, The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils, Neuropharmacology, 44, 516, 10.1016/S0028-3908(03)00023-6 Sajdyk, 2008, Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia, J Neurosci, 28, 893, 10.1523/JNEUROSCI.0659-07.2008 Salome, 2006, Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats, Psychopharmacology (Berl), 187, 237, 10.1007/s00213-006-0424-1 Scantamburlo, 2007, Plasma oxytocin levels and anxiety in patients with major depression, Psychoneuroendocrinology, 32, 407, 10.1016/j.psyneuen.2007.01.009 Schulz, 1996, CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors, Proc Natl Acad Sci USA, 93, 10477, 10.1073/pnas.93.19.10477 Shepherd, 1994, Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety, Psychopharmacology (Berl), 116, 56, 10.1007/BF02244871 Sherrin, 2009, Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system, Mol Psychiatry, 14, 291, 10.1038/sj.mp.4002121 Shimazaki, 2006, The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats, Eur J Pharmacol, 543, 63, 10.1016/j.ejphar.2006.06.032 Simon, 2008, Vasopressin antagonists as anxiolytics and antidepressants: recent developments, Recent Pat CNS Drug Discov, 3, 77, 10.2174/157488908784534586 Singh, 1991, Evidence for an involvement of the brain cholecystokinin B receptor in anxiety, Proc Natl Acad Sci USA, 88, 1130, 10.1073/pnas.88.4.1130 Slattery, 2009, Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats, Neuropharmacology Smagin, 2001, The role of CRH in behavioral responses to stress, Peptides, 22, 713, 10.1016/S0196-9781(01)00384-9 Sorensen, 2004, Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation, J Neurosci Res, 77, 723, 10.1002/jnr.20200 Spiga, 2006, Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons, Neuroscience, 138, 1265, 10.1016/j.neuroscience.2005.12.051 Stemmelin, 2005, Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415, Neuropsychopharmacology, 30, 35, 10.1038/sj.npp.1300562 Stogner, 2000, Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats, Eur J Pharmacol, 387, R9, 10.1016/S0014-2999(99)00800-6 Swanson, 2005, Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299, Proc Natl Acad Sci USA, 102, 17489, 10.1073/pnas.0508970102 Takahashi, 2001, Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety, Brain Res, 902, 135, 10.1016/S0006-8993(01)02405-2 Takahashi, 1989, Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats, Behav Neurosci, 103, 648, 10.1037/0735-7044.103.3.648 Tan, 2008, Repeated intracerebral teneurin C-terminal associated peptide (TCAP)-1 injections produce enduring changes in behavioral responses to corticotropin-releasing factor (CRF) in rat models of anxiety, Behav Brain Res, 188, 195, 10.1016/j.bbr.2007.10.032 Tanaka, 2008, Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice, Brain Res Bull, 75, 509, 10.1016/j.brainresbull.2007.08.009 Teixeira, 2003, Involvement of tachykinin NK1 receptor in the behavioral and immunological responses to swimming stress in mice, Neuropeptides, 37, 307, 10.1016/j.npep.2003.08.002 Teixeira, 2004, Behavioral and immunological effects of substance P in female and male mice, Pharmacol Biochem Behav, 79, 1, 10.1016/j.pbb.2004.04.032 Teixeira, 1996, Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice, Eur J Pharmacol, 311, 7, 10.1016/0014-2999(96)00390-1 Treit, 1990, A comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics, Pharmacol Biochem Behav, 36, 203, 10.1016/0091-3057(90)90151-7 Treit, 1993, Anxiogenic stimuli in the elevated plus-maze, Pharmacol Biochem Behav, 44, 463, 10.1016/0091-3057(93)90492-C Trubiani, 2007, Teneurin carboxy (C)-terminal associated peptide-1 inhibits alkalosis-associated necrotic neuronal death by stimulating superoxide dismutase and catalase activity in immortalized mouse hypothalamic cells, Brain Res, 1176, 27, 10.1016/j.brainres.2007.07.087 Valdez, 2002, Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide, Brain Res, 943, 142, 10.1016/S0006-8993(02)02707-5 Valdez, 2003, Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist, Brain Res, 980, 206, 10.1016/S0006-8993(03)02971-8 Vale, 1981, Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin, Science, 213, 1394, 10.1126/science.6267699 van der Velde, 1983, Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness, Peptides, 4, 297, 10.1016/0196-9781(83)90136-5 van Londen, 1997, Plasma levels of arginine vasopressin elevated in patients with major depression, Neuropsychopharmacology, 17, 284, 10.1016/S0893-133X(97)00054-7 van Megen, 1997, The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients, Psychopharmacology (Berl), 129, 243, 10.1007/s002130050186 Van Pett, 2000, Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse, J Comp Neurol, 428, 191, 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U Varty, 2002, The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists, Neuropsychopharmacology, 27, 371, 10.1016/S0893-133X(02)00313-5 Vaughan, 1995, Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor, Nature, 378, 287, 10.1038/378287a0 Versteeg, 1982, Neurohypophyseal hormones and brain neurochemistry, Pharmacol Ther, 19, 297, 10.1016/0163-7258(82)90071-7 Vivian, 1997, Ultrasonic vocalizations in rat pups: modulation at the gamma-aminobutyric acidA receptor complex and the neurosteroid recognition site, J Pharmacol Exp Ther, 282, 318 Wahlsten, 2003, Different data from different labs: lessons from studies of gene-environment interaction, J Neurobiol, 54, 283, 10.1002/neu.10173 Wang, 2005, Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats, Neurosci Biobehav Rev, 29, 1361, 10.1016/j.neubiorev.2005.05.008 Wang, 2005, Teneurin proteins possess a carboxy terminal sequence with neuromodulatory activity, Brain Res Mol Brain Res, 133, 253, 10.1016/j.molbrainres.2004.10.019 Weiss, 1998, Galanin: a significant role in depression?, Ann N Y Acad Sci, 863, 364, 10.1111/j.1749-6632.1998.tb10707.x Wigger, 2004, Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin, Neuropsychopharmacology, 29, 1, 10.1038/sj.npp.1300290 Willner, 1992, Chronic mild stress-induced anhedonia: a realistic animal model of depression, Neurosci Biobehav Rev, 16, 525, 10.1016/S0149-7634(05)80194-0 Willner, 1987, Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant, Psychopharmacology (Berl), 93, 358, 10.1007/BF00187257 Wilson, 1998, CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze, Psychopharmacology (Berl), 137, 120, 10.1007/s002130050601 Windle, 1997, Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats, Endocrinology, 138, 2829, 10.1210/en.138.7.2829 Yamano, 2000, Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice, J Pharmacol Exp Ther, 292, 181 Yoshimura, 1993, Localization of oxytocin receptor messenger ribonucleic acid in the rat brain, Endocrinology, 133, 1239, 10.1210/en.133.3.1239 Zadina, 1997, A potent and selective endogenous agonist for the mu-opiate receptor, Nature, 386, 499, 10.1038/386499a0 Zhao, 2007, Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats, J Pharmacol Exp Ther, 323, 846, 10.1124/jpet.107.123208 Zobel, 2000, Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated, J Psychiatr Res, 34, 171, 10.1016/S0022-3956(00)00016-9